Loading...
Docoh

Oncocyte (OCX)

Employees
Data from SEC filings
Employee count
Shareholder alignment
Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

Our 2021 annual meeting of shareholders was held on June 24, 2021. At the meeting our shareholders elected seven directors to serve until the next annual meeting of shareholders and until their successors are duly elected and qualified. Our shareholders also ratified the Board of Directors’ selection of OUM & Co. LLP as our independent registered public accountants to audit our financial statements for the current fiscal year; approved an amendment of our Articles of Incorporation to increase the authorized number of shares of common stock, no par value, that we may issue from 150,000,000 shares to 230,000,000 shares (the “Common Stock Amendment”); approved an amendment of our Articles of Incorporation to change our corporate name from OncoCyte Corporation to Oncocyte Corporation (the “Name Change Amendment”); and approved an amendment to our 2018 Equity Incentive Plan (the “Plan”) to make an additional 10,000,000 shares of common stock available for equity awards (the “Incentive Plan Amendment”).

There were 89,833,751 shares of Oncocyte common stock outstanding and eligible to vote at the annual meeting as of the close of business on May 10, 2021, the record date for determining shareholders entitled to vote at the meeting. There were 75,799,133 shares of common stock, or 84.38% of the voting power, represented at the meeting, either in person or by proxy. The following tables show the votes cast by our shareholders and any abstentions with respect to the matters presented to shareholders for a vote at the meeting. Information is also provided as to broker non-votes. A “broker non-vote” occurs when a shareholder whose shares are held in “street name” in a brokerage account or similar account does not instruct the shareholder’s broker or other nominee in whose name the shares are registered how to vote on a matter as to which brokers and nominees are not permitted to vote without instructions from their client.

Election of Directors

Each of the following directors was elected by the following vote:

NomineeVotes ForVotes Withheld
Ronald Andrews58,138,626159,558
Andrew Arno57,870,320427,864
Jennifer Levin-Carter58,115,065183,119
Melinda Griffith58,142,246155,938
Alfred D. Kingsley48,144,92710,153,257
Andrew J. Last57,189,9431,108,241
Cavan Redmond57,754,967543,217

In addition, there were 17,500,949 broker non-votes with respect to the election of directors.

2



Ratification of Appointment of Independent Registered Public Accountants

The appointment of OUM & Co. LLP as our independent registered public accountants for the fiscal year ending December 31, 2021 was ratified by the following vote:

Shares Voted
For75,616,922
Against32,915
Abstain149,296

There were no broker non-votes on this matter.

Common Stock Amendment

The Common Stock Amendment to amend Oncocyte’s Articles of Incorporation to increase the authorized number of shares of common stock from 150,000,000 shares to 230,000,000 shares was approved by the following vote:

Shares Voted
For69,545,450
Against6,141,103
Abstain112,577

There were no broker non-votes on this matter.

Name Change Amendment

The Name Change Amendment to amend our Articles of Incorporation to change our corporate name from OncoCyte Corporation to Oncocyte Corporation was approved by the following vote:

Shares Voted
For75,644,861
Against71,616
Abstain82,653

There were no broker non-votes on this matter.

Incentive Plan Amendment

The Incentive Plan Amendment to make an additional 10,000,000 shares of our common stock available for equity awards was approved by the following vote:

Shares Voted
For49,427,528
Against8,767,756
Abstain102,900

There were 17,500,949 broker non-votes on this matter.